OncLive.com
@onclive
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
ID: 43051682
http://www.onclive.com 28-05-2009 05:04:27
104,104K Tweet
45,45K Followers
1,1K Following
Imetelstat Delivers Sustained RBC-TI With No OS Detriment in Lower-Risk MDS Valeria Santini Society of Hematologic Oncology (SOHO) #SOHO2024 #SOHO24 #oncology onclive.com/view/imetelsta…
Coombs takeover resumes after lunch - Beautiful talk by Dr Seymour highlighting the multi-decade journey of inhibiting BCL2 in CLL which has been so transformative for so many patients calliecoombs #SOHO24
Coombs here - had to take a break for meetings during the myeloma session (I also can’t really follow myeloma data anyway - like what actually is the SOC?!) - excited for the upcoming CLL session though! calliecoombs #SOHO24
Talazoparib Plus Pacritinib Aims to Improve the Limitations of Second-Line Therapy in MPNs Fox Chase Cancer Center #mpn #oncology onclive.com/view/talazopar…
Super interesting work on familial CLL. Also - CLL-Polygenic risk score can also help determine which pts with MBL may progress to CLL. calliecoombs #SOHO24
Dr Ahn making a strong case for BTKi discontinuation for (some) CLL pts calliecoombs #SOHO24
Dr Rogers fudged the debate a bit by changing “can” to “should” re BTKi discontinuation (I might have done same if I were assigned her side) - but did a great job making this case calliecoombs #SOHO24
Don’t miss the Annual Oncology Update 2024 on Oct 19! Hear from gilberto lopes and other experts on the latest in oncology, including CAR-T Cell Therapy, Immunotherapy in NSCLC, and more. Sylvester Comprehensive Cancer Center #CancerResearch #OncologyEvent Register today! ow.ly/n4VH50SG8Fp
Dr Wierda discussing best option for high risk CLL pts - I like this slide as a visual for hypothetical length of time on/off therapy based upon therapeutic sequencing calliecoombs #SOHO24
ICYMI: In a previous episode of #OncLiveOnAir, Balazs Halmos, of Montefiore Health System, discusses common AEs associated with the ADCs that are used in #NSCLC and ways to manage and mitigate these toxicities. #oncology #lcsm onclive.com/view/halmos-on…
A soggy Coombs is signing off! (Caught in rain en route to dinner…) Thanks to @onclive for letting me take over for the day! calliecoombs #SOHO24
Tune in to hear more from D. Ross Camidge, MD, PhD, (D. Ross Camidge), of CU Anschutz Medical Campus, as he discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer. #lcsm #LungCancer onclive.com/view/adverse-e…
The next frontier for dostarlimab-gxly plus chemotherapy in primary advanced or recurrent endometrial cancer will be determining which patient subgroups benefit from the addition of a PARP inhibitor. Krish Tewari, MD UCI School of Medicine #gynsm #oncology #MedTwitter onclive.com/view/dostarlim…
Subgroup analyses from the phase 3 DREAMM-7 trial along with topline findings from the phase 3 DREAMM-8 trial further support the use of belantamab mafodotin plus SOC regimens in relapsed/refractory multiple myeloma. European Hematology Association #EHA2024 #mmsm onclive.com/view/dreamm-7-…
Bruce G. Haffty, MD, MS, discusses radiation therapy in node-positive breast cancer that becomes node negative after neoadjuvant chemotherapy. Bruce Haffty Rutgers Cancer Institute RWJBarnabas #bcsm onclive.com/view/nsabp-b-5…